NCT03256877 (TransTuFo) is a clinical trial in Transitional Cell Carcinoma, sponsored by Hull University Teaching Hospitals NHS Trust.

Who is sponsoring NCT03256877?

NCT03256877 is sponsored by Hull University Teaching Hospitals NHS Trust.

What condition does NCT03256877 study?

NCT03256877 studies Transitional Cell Carcinoma.

Is NCT03256877 still recruiting?

NCT03256877 is currently completed. Last updated 29 July 2019.

Last reviewed 2019-07-29 · How we verify

NCT03256877: TransTuFo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detecting Transitional Cell Carcinoma From Haematuria

Completed Last updated 29 July 2019

What this trial tests

trial in Transitional Cell Carcinoma in 750 participants. Completed in 16 May 2019.

Timeline

18 October 2016

Primary endpoint
28 May 2018

16 May 2019

Quick facts

Lead sponsor	Hull University Teaching Hospitals NHS Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	750
Start date	18 October 2016
Primary completion	28 May 2018
Estimated completion	16 May 2019
Sites	1 location across United Kingdom

Conditions studied

Transitional Cell Carcinoma — all drugs for Transitional Cell Carcinoma →

Sponsor

Hull University Teaching Hospitals NHS Trust

Who can join

18 and older, any sex, with Transitional Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To validate ELISAs for the detection of urinary tissue factor (TF) in patients suspected of having bladder cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Transitional Cell Carcinoma

Currently open trials in the same condition.

NCT07485114 — Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , · recruiting
NCT06462001 — BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer · Phase 3 · active not recruiting
NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
NCT02420847 — Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cance · Phase 1, PHASE2 · active not recruiting

Other Hull University Teaching Hospitals NHS Trust trials

Trials by the same sponsor.

NCT07502040 — Impact of Exercise Access on Physio Outcomes Post Knee Replacement · NA · not yet recruiting
NCT07483502 — The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Sur · NA · not yet recruiting
NCT07427550 — Palliative Care and The Terminally Ill Adults (End of Life) Bill · not yet recruiting
NCT06876506 — Identification of B Regulatory Cells by Flow Cytometry · not yet recruiting
NCT07409519 — Nutritional Screening in Cardiovascular Disease · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03256877 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hull University Teaching Hospitals NHS Trust
Last refreshed: 29 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03256877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing